메뉴 건너뛰기




Volumn , Issue , 2013, Pages 1185-1213

Novel Antiplatelet Therapies

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84882613761     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00058-4     Document Type: Chapter
Times cited : (6)

References (168)
  • 1
    • 0037271306 scopus 로고    scopus 로고
    • Scientific and therapeutic advances in antiplatelet therapy
    • Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003, 2:15-28.
    • (2003) Nat Rev Drug Discov , vol.2 , pp. 15-28
    • Bhatt, D.L.1    Topol, E.J.2
  • 2
    • 37249068049 scopus 로고    scopus 로고
    • Platelet activation and atherothrombosis
    • Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
    • (2007) N Engl J Med , vol.357 , pp. 2482-2494
    • Davi, G.1    Patrono, C.2
  • 3
    • 40749114795 scopus 로고    scopus 로고
    • Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function
    • Zimmerman G.A., Weyrich A.S. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008, 28:s17-s24.
    • (2008) Arterioscler Thromb Vasc Biol , vol.28
    • Zimmerman, G.A.1    Weyrich, A.S.2
  • 6
    • 0037180771 scopus 로고    scopus 로고
    • Inflammation in atherosclerosis
    • Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
    • (2002) Nature , vol.420 , pp. 868-874
    • Libby, P.1
  • 7
    • 50449098285 scopus 로고    scopus 로고
    • Mechanisms of thrombus formation
    • Furie B., Furie B.C. Mechanisms of thrombus formation. N Engl J Med 2008, 359:938-949.
    • (2008) N Engl J Med , vol.359 , pp. 938-949
    • Furie, B.1    Furie, B.C.2
  • 8
    • 0023805341 scopus 로고
    • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
    • ISIS-2 (Second International Study of Infarct Survival) Collaborative Group
    • Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988, 2:349-360. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
    • (1988) Lancet , vol.2 , pp. 349-360
  • 9
    • 78751616421 scopus 로고    scopus 로고
    • Antiplatelet therapy in coronary heart disease prevention
    • Kolandaivelu K., Bhatt D.L. Antiplatelet therapy in coronary heart disease prevention. Cardiol Clin 2011, 29:71-85.
    • (2011) Cardiol Clin , vol.29 , pp. 71-85
    • Kolandaivelu, K.1    Bhatt, D.L.2
  • 10
    • 77953676517 scopus 로고    scopus 로고
    • Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?"
    • Croce K. Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?". Circ Cardiovasc Interv 2010, 3:3-5.
    • (2010) Circ Cardiovasc Interv , vol.3 , pp. 3-5
    • Croce, K.1
  • 11
    • 77649126524 scopus 로고    scopus 로고
    • Heart disease and stroke statistics-2010 update: a report from the American Heart Association
    • Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
    • (2010) Circulation , vol.121
    • Lloyd-Jones, D.1    Adams, R.J.2    Brown, T.M.3    Carnethon, M.4    Dai, S.5    De Simone, G.6
  • 12
    • 79959550517 scopus 로고    scopus 로고
    • Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium
    • Mehran R., Rao S.V., Bhatt D.L., Gibson C.M., Caixeta A., Eikelboom J., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011, 123:2736-2747.
    • (2011) Circulation , vol.123 , pp. 2736-2747
    • Mehran, R.1    Rao, S.V.2    Bhatt, D.L.3    Gibson, C.M.4    Caixeta, A.5    Eikelboom, J.6
  • 13
    • 36148940945 scopus 로고    scopus 로고
    • Intensifying platelet inhibition-navigating between Scylla and Charybdis
    • Bhatt D.L. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007, 357:2078-2081.
    • (2007) N Engl J Med , vol.357 , pp. 2078-2081
    • Bhatt, D.L.1
  • 14
    • 77958005516 scopus 로고    scopus 로고
    • Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
    • Mehta S.R., Tanguay J.F., Eikelboom J.W., Jolly S.S., Joyner C.D., Granger C.B., et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010, 376:1233-1243.
    • (2010) Lancet , vol.376 , pp. 1233-1243
    • Mehta, S.R.1    Tanguay, J.F.2    Eikelboom, J.W.3    Jolly, S.S.4    Joyner, C.D.5    Granger, C.B.6
  • 15
    • 34248352504 scopus 로고    scopus 로고
    • Aspirin dose for the prevention of cardiovascular disease: a systematic review
    • Campbell C.L., Smyth S., Montalescot G., Steinhubl S.R. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007, 297:2018-2024.
    • (2007) JAMA , vol.297 , pp. 2018-2024
    • Campbell, C.L.1    Smyth, S.2    Montalescot, G.3    Steinhubl, S.R.4
  • 16
    • 38949153807 scopus 로고    scopus 로고
    • Historical review: megakaryopoiesis and thrombopoiesis
    • Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 2008, 111:981-986.
    • (2008) Blood , vol.111 , pp. 981-986
    • Kaushansky, K.1
  • 18
    • 79954633893 scopus 로고    scopus 로고
    • Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings
    • Kolandaivelu K., Swaminathan R., Gibson W.J., Kolachalama V.B., Nguyen-Ehrenreich K.L., Giddings V.L., et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011, 123:1400-1409.
    • (2011) Circulation , vol.123 , pp. 1400-1409
    • Kolandaivelu, K.1    Swaminathan, R.2    Gibson, W.J.3    Kolachalama, V.B.4    Nguyen-Ehrenreich, K.L.5    Giddings, V.L.6
  • 19
    • 0032483550 scopus 로고    scopus 로고
    • Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow
    • Savage B., Almus-Jacobs F., Ruggeri Z.M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998, 94:657-666.
    • (1998) Cell , vol.94 , pp. 657-666
    • Savage, B.1    Almus-Jacobs, F.2    Ruggeri, Z.M.3
  • 20
    • 0036851876 scopus 로고    scopus 로고
    • Platelets in atherothrombosis
    • Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234.
    • (2002) Nat Med , vol.8 , pp. 1227-1234
    • Ruggeri, Z.M.1
  • 21
    • 0034066977 scopus 로고    scopus 로고
    • Old concepts and new developments in the study of platelet aggregation
    • Ruggeri Z.M. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000, 105:699-701.
    • (2000) J Clin Invest , vol.105 , pp. 699-701
    • Ruggeri, Z.M.1
  • 22
    • 0036090365 scopus 로고    scopus 로고
    • Shear-dependent tether formation during platelet translocation on von Willebrand factor
    • Dopheide S.M., Maxwell M.J., Jackson S.P. Shear-dependent tether formation during platelet translocation on von Willebrand factor. Blood 2002, 99:159-167.
    • (2002) Blood , vol.99 , pp. 159-167
    • Dopheide, S.M.1    Maxwell, M.J.2    Jackson, S.P.3
  • 23
    • 0038494921 scopus 로고    scopus 로고
    • Platelet-collagen interaction: Is GPVI the central receptor?
    • Nieswandt B., Watson S.P. Platelet-collagen interaction: Is GPVI the central receptor?. Blood 2003, 102:449-461.
    • (2003) Blood , vol.102 , pp. 449-461
    • Nieswandt, B.1    Watson, S.P.2
  • 24
    • 75949128633 scopus 로고    scopus 로고
    • Antiplatelet therapies for the treatment of cardiovascular disease
    • Michelson A.D. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010, 9:154-169.
    • (2010) Nat Rev Drug Discov , vol.9 , pp. 154-169
    • Michelson, A.D.1
  • 26
    • 0035824895 scopus 로고    scopus 로고
    • CD40 signaling and plaque instability
    • Schonbeck U., Libby P. CD40 signaling and plaque instability. Circ Res 2001, 89:1092-1103.
    • (2001) Circ Res , vol.89 , pp. 1092-1103
    • Schonbeck, U.1    Libby, P.2
  • 28
    • 0037065502 scopus 로고    scopus 로고
    • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
    • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
    • (2002) BMJ , vol.324 , pp. 71-86
  • 29
    • 46049108934 scopus 로고    scopus 로고
    • Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
    • Patrono C., Baigent C., Hirsh J., Roth G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:199S-233S.
    • (2008) Chest , vol.133
    • Patrono, C.1    Baigent, C.2    Hirsh, J.3    Roth, G.4
  • 30
    • 65849268320 scopus 로고    scopus 로고
    • Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
    • Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
    • (2009) Lancet , vol.373 , pp. 1849-1860
    • Baigent, C.1    Blackwell, L.2    Collins, R.3    Emberson, J.4    Godwin, J.5    Peto, R.6
  • 31
    • 84882712809 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa antagonists. Development of abciximab and pharmacology of abciximab, tirofiban, and eptifibatide
    • Humana Press, Totowa, NJ, A.M. Lincoff (Ed.)
    • Coller B.S. Glycoprotein IIb/IIIa antagonists. Development of abciximab and pharmacology of abciximab, tirofiban, and eptifibatide. Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease 2003, 73-101. Humana Press, Totowa, NJ. A.M. Lincoff (Ed.).
    • (2003) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease , pp. 73-101
    • Coller, B.S.1
  • 32
    • 80053289254 scopus 로고    scopus 로고
    • The evolution of antiplatelet therapy in cardiovascular disease
    • Yousuf O., Bhatt D.L. The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 2011, 8(10):547-559.
    • (2011) Nat Rev Cardiol , vol.8 , Issue.10 , pp. 547-559
    • Yousuf, O.1    Bhatt, D.L.2
  • 33
    • 0037005777 scopus 로고    scopus 로고
    • Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
    • Bhatt D.L., Bertrand M.E., Berger P.B., L'Allier P.L., Moussa I., Moses J.W., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002, 39:9-14.
    • (2002) J Am Coll Cardiol , vol.39 , pp. 9-14
    • Bhatt, D.L.1    Bertrand, M.E.2    Berger, P.B.3    L'Allier, P.L.4    Moussa, I.5    Moses, J.W.6
  • 34
    • 77955013649 scopus 로고    scopus 로고
    • Overcoming "resistance" to antiplatelet therapy: targeting the issue of nonadherence
    • Kolandaivelu K., Bhatt D.L. Overcoming "resistance" to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol 2010, 7:461-467.
    • (2010) Nat Rev Cardiol , vol.7 , pp. 461-467
    • Kolandaivelu, K.1    Bhatt, D.L.2
  • 35
    • 0030590746 scopus 로고    scopus 로고
    • A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    • CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
    • (1996) Lancet , vol.348 , pp. 1329-1339
    • CAPRIE Steering Committee1
  • 36
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
    • (2001) N Engl J Med , vol.345 , pp. 494-502
    • Yusuf, S.1    Zhao, F.2    Mehta, S.R.3    Chrolavicius, S.4    Tognoni, G.5    Fox, K.K.6
  • 37
    • 0035908781 scopus 로고    scopus 로고
    • Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
    • Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
    • (2001) Lancet , vol.358 , pp. 527-533
    • Mehta, S.R.1    Yusuf, S.2    Peters, R.J.3    Bertrand, M.E.4    Lewis, B.S.5    Natarajan, M.K.6
  • 38
    • 33645861080 scopus 로고    scopus 로고
    • Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    • Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717.
    • (2006) N Engl J Med , vol.354 , pp. 1706-1717
    • Bhatt, D.L.1    Fox, K.A.2    Hacke, W.3    Berger, P.B.4    Black, H.R.5    Boden, W.E.6
  • 39
    • 34247869852 scopus 로고    scopus 로고
    • Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    • Bhatt D.L., Flather M.D., Hacke W., Berger P.B., Black H.R., Boden W.E., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007, 49:1982-1988.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1982-1988
    • Bhatt, D.L.1    Flather, M.D.2    Hacke, W.3    Berger, P.B.4    Black, H.R.5    Boden, W.E.6
  • 41
    • 27744516843 scopus 로고    scopus 로고
    • Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High oral doses for Immediate Clopidogrel Effect) trial
    • von Beckerath N., Taubert D., Pogatsa-Murray G., Schomig E., Kastrati A., Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 High oral doses for Immediate Clopidogrel Effect) trial. Circulation 2005, 112:2946-2950.
    • (2005) Circulation , vol.112 , pp. 2946-2950
    • von Beckerath, N.1    Taubert, D.2    Pogatsa-Murray, G.3    Schomig, E.4    Kastrati, A.5    Schomig, A.6
  • 42
    • 37349111065 scopus 로고    scopus 로고
    • Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
    • Wiviott S.D., Trenk D., Frelinger A.L., O'Donoghue M., Neumann F.J., Michelson A.D., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007, 116:2923-2932.
    • (2007) Circulation , vol.116 , pp. 2923-2932
    • Wiviott, S.D.1    Trenk, D.2    Frelinger, A.L.3    O'Donoghue, M.4    Neumann, F.J.5    Michelson, A.D.6
  • 43
    • 33646596912 scopus 로고    scopus 로고
    • Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial
    • Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673.
    • (2006) Lancet , vol.367 , pp. 1665-1673
    • Halkes, P.H.1    van Gijn, J.2    Kappelle, L.J.3    Koudstaal, P.J.4    Algra, A.5
  • 44
    • 51449116270 scopus 로고    scopus 로고
    • Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
    • Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008, 359:1238-1251.
    • (2008) N Engl J Med , vol.359 , pp. 1238-1251
    • Sacco, R.L.1    Diener, H.C.2    Yusuf, S.3    Cotton, D.4    Ounpuu, S.5    Lawton, W.A.6
  • 45
    • 78650097647 scopus 로고    scopus 로고
    • Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions
    • 1041 e1031.
    • Mauri L., Kereiakes D.J., Normand S.L., Wiviott S.D., Cohen D.J., Holmes D.R., et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010, 160:1035-1041. 1041 e1031.
    • (2010) Am Heart J , vol.160 , pp. 1035-1041
    • Mauri, L.1    Kereiakes, D.J.2    Normand, S.L.3    Wiviott, S.D.4    Cohen, D.J.5    Holmes, D.R.6
  • 47
    • 37349035313 scopus 로고    scopus 로고
    • Late coronary stent thrombosis
    • Windecker S., Meier B. Late coronary stent thrombosis. Circulation 2007, 116:1952-1965.
    • (2007) Circulation , vol.116 , pp. 1952-1965
    • Windecker, S.1    Meier, B.2
  • 48
    • 77950249728 scopus 로고    scopus 로고
    • Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients
    • e501.
    • Dauerman H.L., Bhatt D.L., Gretler D.D., French P.A., Smyth S.S., Becker R.C. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J 2010, 159:508-517. e501.
    • (2010) Am Heart J , vol.159 , pp. 508-517
    • Dauerman, H.L.1    Bhatt, D.L.2    Gretler, D.D.3    French, P.A.4    Smyth, S.S.5    Becker, R.C.6
  • 50
    • 69249219295 scopus 로고    scopus 로고
    • Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit?
    • Bhatt D.L. Tailoring antiplatelet therapy based on pharmacogenomics: How well do the data fit?. JAMA 2009, 302:896-897.
    • (2009) JAMA , vol.302 , pp. 896-897
    • Bhatt, D.L.1
  • 52
    • 69249219296 scopus 로고    scopus 로고
    • Association of cytochrome P450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    • Shuldiner A.R., O'Connell J.R., Bliden K.P., Gandhi A., Ryan K., Horenstein R.B., et al. Association of cytochrome P450 2c19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
    • (2009) JAMA , vol.302 , pp. 849-857
    • Shuldiner, A.R.1    O'Connell, J.R.2    Bliden, K.P.3    Gandhi, A.4    Ryan, K.5    Horenstein, R.B.6
  • 53
    • 76349098199 scopus 로고    scopus 로고
    • Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    • Sibbing D., Koch W., Gebhard D., Schuster T., Braun S., Stegherr J., et al. Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010, 121:512-518.
    • (2010) Circulation , vol.121 , pp. 512-518
    • Sibbing, D.1    Koch, W.2    Gebhard, D.3    Schuster, T.4    Braun, S.5    Stegherr, J.6
  • 55
    • 67649654260 scopus 로고    scopus 로고
    • Antiplatelet drug "resistance". Part 1: mechanisms and clinical measurements
    • Sweeny J.M., Gorog D.A., Fuster V. Antiplatelet drug "resistance". Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009, 6:273-282.
    • (2009) Nat Rev Cardiol , vol.6 , pp. 273-282
    • Sweeny, J.M.1    Gorog, D.A.2    Fuster, V.3
  • 56
    • 67651173161 scopus 로고    scopus 로고
    • Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON TIMI-38 trial
    • Michelson A.D., Frelinger A.L., Braunwald E., Downey W.E., Angiolillo D.J., Xenopoulos N.P., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON TIMI-38 trial. Eur Heart J 2009, 30:1753-1763.
    • (2009) Eur Heart J , vol.30 , pp. 1753-1763
    • Michelson, A.D.1    Frelinger, A.L.2    Braunwald, E.3    Downey, W.E.4    Angiolillo, D.J.5    Xenopoulos, N.P.6
  • 58
    • 77249113768 scopus 로고    scopus 로고
    • Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
    • Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J., Bal E.T., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
    • (2010) JAMA , vol.303 , pp. 754-762
    • Breet, N.J.1    van Werkum, J.W.2    Bouman, H.J.3    Kelder, J.C.4    Ruven, H.J.5    Bal, E.T.6
  • 59
    • 58149476444 scopus 로고    scopus 로고
    • Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
    • Bonello L., Camoin-Jau L., Armero S., Com O., Arques S., Burignat-Bonello C., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103:5-10.
    • (2009) Am J Cardiol , vol.103 , pp. 5-10
    • Bonello, L.1    Camoin-Jau, L.2    Armero, S.3    Com, O.4    Arques, S.5    Burignat-Bonello, C.6
  • 60
    • 80052573217 scopus 로고    scopus 로고
    • Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial
    • Price M.J., Angiolillo D.J., Teirstein P.S., Lillie E., Manoukian S.V., Berger P.B., et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 2011, 124:1132-1137.
    • (2011) Circulation , vol.124 , pp. 1132-1137
    • Price, M.J.1    Angiolillo, D.J.2    Teirstein, P.S.3    Lillie, E.4    Manoukian, S.V.5    Berger, P.B.6
  • 62
    • 75549086129 scopus 로고    scopus 로고
    • Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
    • Bhatt D.L. Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?. Nat Rev Cardiol 2009, 6:737-738.
    • (2009) Nat Rev Cardiol , vol.6 , pp. 737-738
    • Bhatt, D.L.1
  • 66
    • 77955677366 scopus 로고    scopus 로고
    • Rationale and design of the randomized, double-blind trial testing intravenous and oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-pci)
    • Leonardi S., Rao S.V., Harrington R.A., Bhatt D.L., Gibson C.M., Roe M.T., et al. Rationale and design of the randomized, double-blind trial testing intravenous and oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary interventions patients (INNOVATE-pci). Am Heart J 2010, 160:65-72.
    • (2010) Am Heart J , vol.160 , pp. 65-72
    • Leonardi, S.1    Rao, S.V.2    Harrington, R.A.3    Bhatt, D.L.4    Gibson, C.M.5    Roe, M.T.6
  • 67
    • 84856293074 scopus 로고    scopus 로고
    • 12 inhibitor, in non-urgent pci (abstract 2036)
    • 12 inhibitor, in non-urgent pci (abstract 2036). 2010 ESC Congress 2010.
    • (2010) 2010 ESC Congress
    • Rao, S.V.1
  • 69
    • 0023942501 scopus 로고
    • Diadenosine 5',5'''-p1,p4-tetraphosphate, a potential antithrombotic agent
    • Louie S., Kim B.K., Zamecnik P. Diadenosine 5',5'''-p1,p4-tetraphosphate, a potential antithrombotic agent. Thromb Res 1988, 49:557-565.
    • (1988) Thromb Res , vol.49 , pp. 557-565
    • Louie, S.1    Kim, B.K.2    Zamecnik, P.3
  • 70
    • 0026452776 scopus 로고
    • Antithrombotic effect of beta,beta'-monochloromethylene diadenosine 5',5"'-p1,p4-tetraphosphate
    • Kim B.K., Zamecnik P., Taylor G., Guo M.J., Blackburn G.M. Antithrombotic effect of beta,beta'-monochloromethylene diadenosine 5',5"'-p1,p4-tetraphosphate. Proc Natl Acad Sci USA 1992, 89:11056-11058.
    • (1992) Proc Natl Acad Sci USA , vol.89 , pp. 11056-11058
    • Kim, B.K.1    Zamecnik, P.2    Taylor, G.3    Guo, M.J.4    Blackburn, G.M.5
  • 72
    • 0345540629 scopus 로고    scopus 로고
    • Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation
    • Enjyoji K., Sevigny J., Lin Y., Frenette P.S., Christie P.D., Esch J.S., et al. Targeted disruption of CD39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999, 5:1010-1017.
    • (1999) Nat Med , vol.5 , pp. 1010-1017
    • Enjyoji, K.1    Sevigny, J.2    Lin, Y.3    Frenette, P.S.4    Christie, P.D.5    Esch, J.S.6
  • 73
    • 79952116591 scopus 로고    scopus 로고
    • Identification of a tsetse fly salivary protein with dual inhibitory action on human platelet aggregation
    • Caljon G., De Ridder K., De Baetselier P., Coosemans M., Van Den Abbeele J. Identification of a tsetse fly salivary protein with dual inhibitory action on human platelet aggregation. PLoS One 2010, 5:e9671.
    • (2010) PLoS One , vol.5
    • Caljon, G.1    De Ridder, K.2    De Baetselier, P.3    Coosemans, M.4    Van Den Abbeele, J.5
  • 74
    • 1542269076 scopus 로고    scopus 로고
    • Structure and protein design of a human platelet function inhibitor
    • Dai J., Liu J., Deng Y., Smith T.M., Lu M. Structure and protein design of a human platelet function inhibitor. Cell 2004, 116:649-659.
    • (2004) Cell , vol.116 , pp. 649-659
    • Dai, J.1    Liu, J.2    Deng, Y.3    Smith, T.M.4    Lu, M.5
  • 75
    • 0027958181 scopus 로고
    • Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury
    • Lee M., Cryer B., Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994, 120:184-189.
    • (1994) Ann Intern Med , vol.120 , pp. 184-189
    • Lee, M.1    Cryer, B.2    Feldman, M.3
  • 76
    • 65249135856 scopus 로고    scopus 로고
    • Antithrombotic therapy in heart failure: watchful wondering
    • Konstam M.A. Antithrombotic therapy in heart failure: watchful wondering. Circulation 2009, 119:1559-1561.
    • (2009) Circulation , vol.119 , pp. 1559-1561
    • Konstam, M.A.1
  • 77
    • 65949110335 scopus 로고    scopus 로고
    • Tp receptor antagonism: a new concept in atherothrombosis and stroke prevention
    • Chamorro A. Tp receptor antagonism: a new concept in atherothrombosis and stroke prevention. Cerebrovasc Dis 2009, 27(Suppl. 3):20-27.
    • (2009) Cerebrovasc Dis , vol.27 , Issue.SUPPL. 3 , pp. 20-27
    • Chamorro, A.1
  • 78
    • 25444465119 scopus 로고    scopus 로고
    • Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study
    • Viles-Gonzalez J.F., Fuster V., Corti R., Valdiviezo C., Hutter R., Corda S., et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005, 26:1557-1561.
    • (2005) Eur Heart J , vol.26 , pp. 1557-1561
    • Viles-Gonzalez, J.F.1    Fuster, V.2    Corti, R.3    Valdiviezo, C.4    Hutter, R.5    Corda, S.6
  • 79
    • 79958770159 scopus 로고    scopus 로고
    • Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
    • Bousser M.G., Amarenco P., Chamorro A., Fisher M., Ford I., Fox K.M., et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011, 377:2013-2022.
    • (2011) Lancet , vol.377 , pp. 2013-2022
    • Bousser, M.G.1    Amarenco, P.2    Chamorro, A.3    Fisher, M.4    Ford, I.5    Fox, K.M.6
  • 80
    • 79958765190 scopus 로고    scopus 로고
    • Vascular events after stroke: terutroban fails to perform
    • Lee M., Ovbiagele B. Vascular events after stroke: terutroban fails to perform. Lancet 2011, 377:1980-1982.
    • (2011) Lancet , vol.377 , pp. 1980-1982
    • Lee, M.1    Ovbiagele, B.2
  • 82
    • 0344737009 scopus 로고    scopus 로고
    • The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected cos-7 cells
    • Qiao N., Reynaud D., Demin P., Halushka P.V., Pace-Asciak C.R. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPalpha isoform in transfected cos-7 cells. J Pharmacol Exp Ther 2003, 307:1142-1147.
    • (2003) J Pharmacol Exp Ther , vol.307 , pp. 1142-1147
    • Qiao, N.1    Reynaud, D.2    Demin, P.3    Halushka, P.V.4    Pace-Asciak, C.R.5
  • 83
    • 0025203077 scopus 로고
    • Cardioprotective actions of the specific thromboxane receptor antagonist (+)-s145na following coronary occlusion and reperfusion in the rat
    • Tsao P.S., Lefer A.M. Cardioprotective actions of the specific thromboxane receptor antagonist (+)-s145na following coronary occlusion and reperfusion in the rat. Res Commun Chem Pathol Pharmacol 1990, 70:205-211.
    • (1990) Res Commun Chem Pathol Pharmacol , vol.70 , pp. 205-211
    • Tsao, P.S.1    Lefer, A.M.2
  • 84
    • 0042386436 scopus 로고    scopus 로고
    • Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice
    • Ito Y., Katagiri H., Ishii K., Kakita A., Hayashi I., Majima M. Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice. Eur Surg Res 2003, 35:408-416.
    • (2003) Eur Surg Res , vol.35 , pp. 408-416
    • Ito, Y.1    Katagiri, H.2    Ishii, K.3    Kakita, A.4    Hayashi, I.5    Majima, M.6
  • 85
    • 0005556702 scopus 로고    scopus 로고
    • Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane
    • Maassen VanDenBrink A., Bax W.A., Ferrari M.D., Zijlstra F.J., Bos E., Saxena P.R. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br J Pharmacol 1996, 119:855-862.
    • (1996) Br J Pharmacol , vol.119 , pp. 855-862
    • Maassen VanDenBrink, A.1    Bax, W.A.2    Ferrari, M.D.3    Zijlstra, F.J.4    Bos, E.5    Saxena, P.R.6
  • 86
    • 0030611110 scopus 로고    scopus 로고
    • Thromboxane a2 receptor density increases during chronic exposure to thromboxane a2 receptor antagonists after porcine carotid bypass
    • Brothers T.E., Robison J.G., Elliott B.M., Boggs J.M., Halushka P.V. Thromboxane a2 receptor density increases during chronic exposure to thromboxane a2 receptor antagonists after porcine carotid bypass. Cardiovasc Surg 1997, 5:92-98.
    • (1997) Cardiovasc Surg , vol.5 , pp. 92-98
    • Brothers, T.E.1    Robison, J.G.2    Elliott, B.M.3    Boggs, J.M.4    Halushka, P.V.5
  • 89
    • 0028140168 scopus 로고
    • 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus Aspirin Patency Trial (RAPT)
    • 2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus Aspirin Patency Trial (RAPT). Circulation 1994, 89:588-595.
    • (1994) Circulation , vol.89 , pp. 588-595
    • The RAPT Investigators1
  • 90
    • 20244386797 scopus 로고    scopus 로고
    • Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension
    • Langleben D., Christman B.W., Barst R.J., Dias V.C., Galie N., Higenbottam T.W., et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002, 143:E4.
    • (2002) Am Heart J , vol.143
    • Langleben, D.1    Christman, B.W.2    Barst, R.J.3    Dias, V.C.4    Galie, N.5    Higenbottam, T.W.6
  • 92
    • 0027198798 scopus 로고
    • Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP group
    • Balsano F., Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP group. Circulation 1993, 87:1563-1569.
    • (1993) Circulation , vol.87 , pp. 1563-1569
    • Balsano, F.1    Violi, F.2
  • 93
    • 34249856927 scopus 로고    scopus 로고
    • A review of picotamide in the reduction of cardiovascular events in diabetic patients
    • Celestini A., Violi F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manag 2007, 3:93-98.
    • (2007) Vasc Health Risk Manag , vol.3 , pp. 93-98
    • Celestini, A.1    Violi, F.2
  • 94
    • 4944241267 scopus 로고    scopus 로고
    • 2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study
    • 2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004, 25:1845-1852.
    • (2004) Eur Heart J , vol.25 , pp. 1845-1852
    • Neri Serneri, G.G.1    Coccheri, S.2    Marubini, E.3    Violi, F.4
  • 95
  • 96
    • 15444374171 scopus 로고    scopus 로고
    • Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice
    • Momi S., Pitchford S.C., Alberti P.F., Minuz P., Del Soldato P., Gresele P. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thromb Haemost 2005, 93:535-543.
    • (2005) Thromb Haemost , vol.93 , pp. 535-543
    • Momi, S.1    Pitchford, S.C.2    Alberti, P.F.3    Minuz, P.4    Del Soldato, P.5    Gresele, P.6
  • 97
  • 98
    • 34247121053 scopus 로고    scopus 로고
    • Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG
    • Lorusso R., De Cicco G., Beghi C., Gherli T., Poli E., Corradi D., et al. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. Int J Cardiol 2007, 118:164-169.
    • (2007) Int J Cardiol , vol.118 , pp. 164-169
    • Lorusso, R.1    De Cicco, G.2    Beghi, C.3    Gherli, T.4    Poli, E.5    Corradi, D.6
  • 99
    • 0037373349 scopus 로고    scopus 로고
    • Gastrointestinal safety of no-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study
    • Fiorucci S., Santucci L., Gresele P., Faccino R.M., Del Soldato P., Morelli A. Gastrointestinal safety of no-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003, 124:600-607.
    • (2003) Gastroenterology , vol.124 , pp. 600-607
    • Fiorucci, S.1    Santucci, L.2    Gresele, P.3    Faccino, R.M.4    Del Soldato, P.5    Morelli, A.6
  • 100
    • 0035895332 scopus 로고    scopus 로고
    • Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials
    • Chew D.P., Bhatt D.L., Sapp S., Topol E.J. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001, 103:201-206.
    • (2001) Circulation , vol.103 , pp. 201-206
    • Chew, D.P.1    Bhatt, D.L.2    Sapp, S.3    Topol, E.J.4
  • 101
    • 0003215841 scopus 로고    scopus 로고
    • GPIIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation
    • II-318.
    • Nannizzi-Alaimo N., Alves V.L., Prasad S., et al. GPIIb-IIIa antagonists demonstrate a dose-dependent inhibition and potentiation of soluble CD40L (CD154) release during platelet stimulation. Circulation 2001, 104. II-318.
    • (2001) Circulation , vol.104
    • Nannizzi-Alaimo, N.1    Alves, V.L.2    Prasad, S.3
  • 102
    • 0034332785 scopus 로고    scopus 로고
    • Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
    • Cox D., Smith R., Quinn M., Theroux P., Crean P., Fitzgerald D.J. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000, 36:1514-1519.
    • (2000) J Am Coll Cardiol , vol.36 , pp. 1514-1519
    • Cox, D.1    Smith, R.2    Quinn, M.3    Theroux, P.4    Crean, P.5    Fitzgerald, D.J.6
  • 104
    • 0037118664 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?
    • Quinn M.J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa inhibitors: Recognition of a two-edged sword?. Circulation 2002, 106:379-385.
    • (2002) Circulation , vol.106 , pp. 379-385
    • Quinn, M.J.1    Plow, E.F.2    Topol, E.J.3
  • 105
    • 0035028123 scopus 로고    scopus 로고
    • Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion
    • Quinn M.J., Murphy R.T., Dooley M., Foley J.B., Fitzgerald D.J. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 2001, 297:496-500.
    • (2001) J Pharmacol Exp Ther , vol.297 , pp. 496-500
    • Quinn, M.J.1    Murphy, R.T.2    Dooley, M.3    Foley, J.B.4    Fitzgerald, D.J.5
  • 106
    • 38949130475 scopus 로고    scopus 로고
    • Application of high-throughput screening to identify a novel alphaIIb-specific small-molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen
    • Blue R., Murcia M., Karan C., Jirouskova M., Coller B.S. Application of high-throughput screening to identify a novel alphaIIb-specific small-molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. Blood 2008, 111:1248-1256.
    • (2008) Blood , vol.111 , pp. 1248-1256
    • Blue, R.1    Murcia, M.2    Karan, C.3    Jirouskova, M.4    Coller, B.S.5
  • 107
    • 67651068728 scopus 로고    scopus 로고
    • Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist
    • Blue R., Kowalska M.A., Hirsch J., Murcia M., Janczak C.A., Harrington A., et al. Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist. Blood 2009, 114:195-201.
    • (2009) Blood , vol.114 , pp. 195-201
    • Blue, R.1    Kowalska, M.A.2    Hirsch, J.3    Murcia, M.4    Janczak, C.A.5    Harrington, A.6
  • 108
    • 78649747986 scopus 로고    scopus 로고
    • Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening
    • Zhu J., Negri A., Provasi D., Filizola M., Coller B.S., Springer T.A. Closed headpiece of integrin alphaIIbbeta3 and its complex with an alphaIIbbeta3-specific antagonist that does not induce opening. Blood 2010, 116:5050-5059.
    • (2010) Blood , vol.116 , pp. 5050-5059
    • Zhu, J.1    Negri, A.2    Provasi, D.3    Filizola, M.4    Coller, B.S.5    Springer, T.A.6
  • 109
    • 61849180442 scopus 로고    scopus 로고
    • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
    • Becker R.C., Moliterno D.J., Jennings L.K., Pieper K.S., Pei J., Niederman A., et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009, 373:919-928.
    • (2009) Lancet , vol.373 , pp. 919-928
    • Becker, R.C.1    Moliterno, D.J.2    Jennings, L.K.3    Pieper, K.S.4    Pei, J.5    Niederman, A.6
  • 110
    • 33645858005 scopus 로고    scopus 로고
    • Agonists and antagonists of protease activated receptors (PARs)
    • Barry G.D., Le G.T., Fairlie D.P. Agonists and antagonists of protease activated receptors (PARs). Curr Med Chem 2006, 13:243-265.
    • (2006) Curr Med Chem , vol.13 , pp. 243-265
    • Barry, G.D.1    Le, G.T.2    Fairlie, D.P.3
  • 111
  • 112
    • 0034967927 scopus 로고    scopus 로고
    • Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats
    • Andrade-Gordon P., Derian C.K., Maryanoff B.E., Zhang H.C., Addo M.F., Cheung W., et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 2001, 298:34-42.
    • (2001) J Pharmacol Exp Ther , vol.298 , pp. 34-42
    • Andrade-Gordon, P.1    Derian, C.K.2    Maryanoff, B.E.3    Zhang, H.C.4    Addo, M.F.5    Cheung, W.6
  • 113
    • 76549094772 scopus 로고    scopus 로고
    • Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases
    • Siller-Matula J.M., Krumphuber J., Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol 2010, 159:502-517.
    • (2010) Br J Pharmacol , vol.159 , pp. 502-517
    • Siller-Matula, J.M.1    Krumphuber, J.2    Jilma, B.3
  • 114
    • 85027946204 scopus 로고    scopus 로고
    • Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial
    • O'Donoghue M.L., Bhatt D.L., Wiviott S.D., Goodman S.G., Fitzgerald D.J., Angiolillo D.J., et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 2011, 123:1843-1853.
    • (2011) Circulation , vol.123 , pp. 1843-1853
    • O'Donoghue, M.L.1    Bhatt, D.L.2    Wiviott, S.D.3    Goodman, S.G.4    Fitzgerald, D.J.5    Angiolillo, D.J.6
  • 115
    • 84882645953 scopus 로고    scopus 로고
    • US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with acute coronary syndrome (TRACER) 2011.
    • US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with acute coronary syndrome (TRACER) 2011.
  • 116
    • 84882577111 scopus 로고    scopus 로고
    • US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with atherosclerosis (TRA2P TIMI-50). 2010.
    • US NIH Cg. Trial to assess the effects of SCH 530348 in preventing heart attack and stroke in patients with atherosclerosis (TRA2P TIMI-50). 2010.
  • 117
    • 85027951718 scopus 로고    scopus 로고
    • Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial
    • Wiviott S.D., Flather M.D., O'Donoghue M.L., Goto S., Fitzgerald D.J., Cura F., et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation 2011, 123:1854-1863.
    • (2011) Circulation , vol.123 , pp. 1854-1863
    • Wiviott, S.D.1    Flather, M.D.2    O'Donoghue, M.L.3    Goto, S.4    Fitzgerald, D.J.5    Cura, F.6
  • 118
    • 0036797590 scopus 로고    scopus 로고
    • Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation
    • Covic L., Misra M., Badar J., Singh C., Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002, 8:1161-1165.
    • (2002) Nat Med , vol.8 , pp. 1161-1165
    • Covic, L.1    Misra, M.2    Badar, J.3    Singh, C.4    Kuliopulos, A.5
  • 119
    • 34247402058 scopus 로고    scopus 로고
    • Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation
    • Stoll P., Bassler N., Hagemeyer C.E., Eisenhardt S.U., Chen Y.C., Schmidt R., et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 2007, 27:1206-1212.
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 1206-1212
    • Stoll, P.1    Bassler, N.2    Hagemeyer, C.E.3    Eisenhardt, S.U.4    Chen, Y.C.5    Schmidt, R.6
  • 120
    • 0036162199 scopus 로고    scopus 로고
    • Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons
    • Wu D., Meiring M., Kotze H.F., Deckmyn H., Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002, 22:323-328.
    • (2002) Arterioscler Thromb Vasc Biol , vol.22 , pp. 323-328
    • Wu, D.1    Meiring, M.2    Kotze, H.F.3    Deckmyn, H.4    Cauwenberghs, N.5
  • 121
    • 0028361191 scopus 로고
    • Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates
    • Cadroy Y., Hanson S.R., Kelly A.B., Marzec U.M., Evatt B.L., Kunicki T.J., et al. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 1994, 83:3218-3224.
    • (1994) Blood , vol.83 , pp. 3218-3224
    • Cadroy, Y.1    Hanson, S.R.2    Kelly, A.B.3    Marzec, U.M.4    Evatt, B.L.5    Kunicki, T.J.6
  • 122
    • 0036917764 scopus 로고    scopus 로고
    • Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets
    • Alimardani G., Guichard J., Fichelson S., Cramer E.M. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. Thromb Haemost 2002, 88:1039-1046.
    • (2002) Thromb Haemost , vol.88 , pp. 1039-1046
    • Alimardani, G.1    Guichard, J.2    Fichelson, S.3    Cramer, E.M.4
  • 123
    • 54949095069 scopus 로고    scopus 로고
    • The humanized anti-glycoprotein Ib monoclonal antibody h6b4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons
    • Fontayne A., Meiring M., Lamprecht S., Roodt J., Demarsin E., Barbeaux P., et al. The humanized anti-glycoprotein Ib monoclonal antibody h6b4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008, 100:670-677.
    • (2008) Thromb Haemost , vol.100 , pp. 670-677
    • Fontayne, A.1    Meiring, M.2    Lamprecht, S.3    Roodt, J.4    Demarsin, E.5    Barbeaux, P.6
  • 124
    • 0032031490 scopus 로고    scopus 로고
    • Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of crotalus atrox
    • Chang M.C., Lin H.K., Peng H.C., Huang T.F. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of crotalus atrox. Blood 1998, 91:1582-1589.
    • (1998) Blood , vol.91 , pp. 1582-1589
    • Chang, M.C.1    Lin, H.K.2    Peng, H.C.3    Huang, T.F.4
  • 125
    • 0031805437 scopus 로고    scopus 로고
    • The CDNA cloning and molecular characterization of a snake venom platelet glycoprotein Ib-binding protein, mamushigin, from agkistrodon halys blomhoffii venom
    • Sakurai Y., Fujimura Y., Kokubo T., Imamura K., Kawasaki T., Handa M., et al. The CDNA cloning and molecular characterization of a snake venom platelet glycoprotein Ib-binding protein, mamushigin, from agkistrodon halys blomhoffii venom. Thromb Haemost 1998, 79:1199-1207.
    • (1998) Thromb Haemost , vol.79 , pp. 1199-1207
    • Sakurai, Y.1    Fujimura, Y.2    Kokubo, T.3    Imamura, K.4    Kawasaki, T.5    Handa, M.6
  • 126
    • 0028804347 scopus 로고
    • Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries
    • Azzam K., Garfinkel L.I., Bal dit Sollier C., Cisse Thiam M., Drouet L. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb Haemost 1995, 73:318-323.
    • (1995) Thromb Haemost , vol.73 , pp. 318-323
    • Azzam, K.1    Garfinkel, L.I.2    Bal dit Sollier, C.3    Cisse Thiam, M.4    Drouet, L.5
  • 127
    • 0028641293 scopus 로고
    • Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain
    • McGhie A.I., McNatt J., Ezov N., Cui K., Mower L.K., Hagay Y., et al. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation 1994, 90:2976-2981.
    • (1994) Circulation , vol.90 , pp. 2976-2981
    • McGhie, A.I.1    McNatt, J.2    Ezov, N.3    Cui, K.4    Mower, L.K.5    Hagay, Y.6
  • 129
    • 0035279906 scopus 로고    scopus 로고
    • Anti-human VWF monoclonal antibody, AJVW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs
    • Kageyama S., Yamamoto H., Nakazawa H., Yoshimoto R. Anti-human VWF monoclonal antibody, AJVW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001, 101:395-404.
    • (2001) Thromb Res , vol.101 , pp. 395-404
    • Kageyama, S.1    Yamamoto, H.2    Nakazawa, H.3    Yoshimoto, R.4
  • 130
    • 0029917899 scopus 로고    scopus 로고
    • Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium
    • Owens M.R., Holme S. Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium. Thromb Res 1996, 81:177-185.
    • (1996) Thromb Res , vol.81 , pp. 177-185
    • Owens, M.R.1    Holme, S.2
  • 131
    • 0029123084 scopus 로고
    • Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions
    • Golino P., Ragni M., Cirillo P., Pascucci I., Ezekowitz M.D., Pawashe A., et al. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thromb Haemost 1995, 74:974-979.
    • (1995) Thromb Haemost , vol.74 , pp. 974-979
    • Golino, P.1    Ragni, M.2    Cirillo, P.3    Pascucci, I.4    Ezekowitz, M.D.5    Pawashe, A.6
  • 132
    • 67650236718 scopus 로고    scopus 로고
    • ARC-1779, a pegylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent
    • Cosmi B. ARC-1779, a pegylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr Opin Mol Ther 2009, 11:322-328.
    • (2009) Curr Opin Mol Ther , vol.11 , pp. 322-328
    • Cosmi, B.1
  • 134
    • 79961210182 scopus 로고    scopus 로고
    • The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial
    • Markus H.S., McCollum C., Imray C., Goulder M.A., Gilbert J., King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: a randomized trial. Stroke 2011, 42:2149-2153.
    • (2011) Stroke , vol.42 , pp. 2149-2153
    • Markus, H.S.1    McCollum, C.2    Imray, C.3    Goulder, M.A.4    Gilbert, J.5    King, A.6
  • 135
    • 37349040378 scopus 로고    scopus 로고
    • First-in-human evaluation of anti von Willebrand factor therapeutic aptamer arc1779 in healthy volunteers
    • Gilbert J.C., DeFeo-Fraulini T., Hutabarat R.M., Horvath C.J., Merlino P.G., Marsh H.N., et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer arc1779 in healthy volunteers. Circulation 2007, 116:2678-2686.
    • (2007) Circulation , vol.116 , pp. 2678-2686
    • Gilbert, J.C.1    DeFeo-Fraulini, T.2    Hutabarat, R.M.3    Horvath, C.J.4    Merlino, P.G.5    Marsh, H.N.6
  • 137
    • 79960633933 scopus 로고    scopus 로고
    • Toxins in thrombosis and haemostasis: potential beyond imagination
    • Kini R.M. Toxins in thrombosis and haemostasis: potential beyond imagination. J Thromb Haemost 2011, 9(Suppl. 1):195-208.
    • (2011) J Thromb Haemost , vol.9 , Issue.SUPPL. 1 , pp. 195-208
    • Kini, R.M.1
  • 138
    • 49849103616 scopus 로고    scopus 로고
    • A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions
    • Hsu C.C., Wu W.B., Huang T.F. A snake venom metalloproteinase, kistomin, cleaves platelet glycoprotein VI and impairs platelet functions. J Thromb Haemost 2008, 6:1578-1585.
    • (2008) J Thromb Haemost , vol.6 , pp. 1578-1585
    • Hsu, C.C.1    Wu, W.B.2    Huang, T.F.3
  • 139
    • 43049116482 scopus 로고    scopus 로고
    • A novel antiplatelet antibody therapy that induces camp-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex
    • Takayama H., Hosaka Y., Nakayama K., Shirakawa K., Naitoh K., Matsusue T., et al. A novel antiplatelet antibody therapy that induces camp-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest 2008, 118:1785-1795.
    • (2008) J Clin Invest , vol.118 , pp. 1785-1795
    • Takayama, H.1    Hosaka, Y.2    Nakayama, K.3    Shirakawa, K.4    Naitoh, K.5    Matsusue, T.6
  • 140
    • 58849165421 scopus 로고    scopus 로고
    • Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism
    • Miller M.W., Basra S., Kulp D.W., Billings P.C., Choi S., Beavers M.P., et al. Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci U S A 2009, 106:719-724.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 719-724
    • Miller, M.W.1    Basra, S.2    Kulp, D.W.3    Billings, P.C.4    Choi, S.5    Beavers, M.P.6
  • 141
    • 0034663794 scopus 로고    scopus 로고
    • Isolation and characterization of EMS16, a c-lectin type protein from echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin
    • Marcinkiewicz C., Lobb R.R., Marcinkiewicz M.M., Daniel J.L., Smith J.B., Dangelmaier C., et al. Isolation and characterization of EMS16, a c-lectin type protein from echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin. Biochemistry 2000, 39:9859-9867.
    • (2000) Biochemistry , vol.39 , pp. 9859-9867
    • Marcinkiewicz, C.1    Lobb, R.R.2    Marcinkiewicz, M.M.3    Daniel, J.L.4    Smith, J.B.5    Dangelmaier, C.6
  • 142
    • 30444437494 scopus 로고    scopus 로고
    • C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen
    • Lasser G., Guchhait P., Ellsworth J.L., Sheppard P., Lewis K., Bishop P., et al. C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood 2006, 107:423-430.
    • (2006) Blood , vol.107 , pp. 423-430
    • Lasser, G.1    Guchhait, P.2    Ellsworth, J.L.3    Sheppard, P.4    Lewis, K.5    Bishop, P.6
  • 143
    • 1442290149 scopus 로고    scopus 로고
    • Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo
    • Massberg S., Konrad I., Bultmann A., Schulz C., Munch G., Peluso M., et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004, 18:397-399.
    • (2004) FASEB J , vol.18 , pp. 397-399
    • Massberg, S.1    Konrad, I.2    Bultmann, A.3    Schulz, C.4    Munch, G.5    Peluso, M.6
  • 144
    • 85027958733 scopus 로고    scopus 로고
    • Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans
    • Ungerer M., Rosport K., Bultmann A., Piechatzek R., Uhland K., Schlieper P., et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011, 123:1891-1899.
    • (2011) Circulation , vol.123 , pp. 1891-1899
    • Ungerer, M.1    Rosport, K.2    Bultmann, A.3    Piechatzek, R.4    Uhland, K.5    Schlieper, P.6
  • 145
    • 0033856462 scopus 로고    scopus 로고
    • PI3-kinase inhibition: A target for drug development?
    • Stein R.C., Waterfield M.D. PI3-kinase inhibition: A target for drug development?. Mol Med Today 2000, 6:347-357.
    • (2000) Mol Med Today , vol.6 , pp. 347-357
    • Stein, R.C.1    Waterfield, M.D.2
  • 147
    • 70349338807 scopus 로고    scopus 로고
    • Apd791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)b en zamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology
    • Adams J.W., Ramirez J., Shi Y., Thomsen W., Frazer J., Morgan M., et al. Apd791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)b en zamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. J Pharmacol Exp Ther 2009, 331:96-103.
    • (2009) J Pharmacol Exp Ther , vol.331 , pp. 96-103
    • Adams, J.W.1    Ramirez, J.2    Shi, Y.3    Thomsen, W.4    Frazer, J.5    Morgan, M.6
  • 149
    • 46249118961 scopus 로고    scopus 로고
    • Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial
    • Shinohara Y., Nishimaru K., Sawada T., Terashi A., Handa S., Hirai S., et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 2008, 39:1827-1833.
    • (2008) Stroke , vol.39 , pp. 1827-1833
    • Shinohara, Y.1    Nishimaru, K.2    Sawada, T.3    Terashi, A.4    Handa, S.5    Hirai, S.6
  • 153
    • 84882587534 scopus 로고    scopus 로고
    • US NIH Cg. Single-dose safety study of APD791 in healthy volunteers. 2008.
    • US NIH Cg. Single-dose safety study of APD791 in healthy volunteers. 2008.
  • 154
    • 24144449528 scopus 로고    scopus 로고
    • Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human
    • Cipollone F., Fazia M.L., Iezzi A., Cuccurullo C., De Cesare D., Ucchino S., et al. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 2005, 25:1925-1931.
    • (2005) Arterioscler Thromb Vasc Biol , vol.25 , pp. 1925-1931
    • Cipollone, F.1    Fazia, M.L.2    Iezzi, A.3    Cuccurullo, C.4    De Cesare, D.5    Ucchino, S.6
  • 157
    • 85047694191 scopus 로고    scopus 로고
    • Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy
    • Angelillo-Scherrer A., Burnier L., Flores N., Savi P., DeMol M., Schaeffer P., et al. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest 2005, 115:237-246.
    • (2005) J Clin Invest , vol.115 , pp. 237-246
    • Angelillo-Scherrer, A.1    Burnier, L.2    Flores, N.3    Savi, P.4    DeMol, M.5    Schaeffer, P.6
  • 158
    • 77952683864 scopus 로고    scopus 로고
    • Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood
    • Ekman C., Stenhoff J., Dahlback B. Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood. J Thromb Haemost 2010, 8:838-844.
    • (2010) J Thromb Haemost , vol.8 , pp. 838-844
    • Ekman, C.1    Stenhoff, J.2    Dahlback, B.3
  • 159
    • 77955799154 scopus 로고    scopus 로고
    • Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes
    • Ekman C., Linder A., Akesson P., Dahlback B. Plasma concentrations of Gas6 (growth arrest specific protein 6) and its soluble tyrosine kinase receptor sAxl in sepsis and systemic inflammatory response syndromes. Crit Care 2010, 14:R158.
    • (2010) Crit Care , vol.14
    • Ekman, C.1    Linder, A.2    Akesson, P.3    Dahlback, B.4
  • 161
    • 0037097589 scopus 로고    scopus 로고
    • Arp2/3 complex is required for actin polymerization during platelet shape change
    • Li Z., Kim E.S., Bearer E.L. Arp2/3 complex is required for actin polymerization during platelet shape change. Blood 2002, 99:4466-4474.
    • (2002) Blood , vol.99 , pp. 4466-4474
    • Li, Z.1    Kim, E.S.2    Bearer, E.L.3
  • 162
    • 12444303861 scopus 로고    scopus 로고
    • Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin
    • Falati S., Liu Q., Gross P., Merrill-Skoloff G., Chou J., Vandendries E., et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003, 197:1585-1598.
    • (2003) J Exp Med , vol.197 , pp. 1585-1598
    • Falati, S.1    Liu, Q.2    Gross, P.3    Merrill-Skoloff, G.4    Chou, J.5    Vandendries, E.6
  • 163
    • 0033574172 scopus 로고    scopus 로고
    • Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
    • Kumar A., Villani M.P., Patel U.K., Keith J.C., Schaub R.G. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 1999, 99:1363-1369.
    • (1999) Circulation , vol.99 , pp. 1363-1369
    • Kumar, A.1    Villani, M.P.2    Patel, U.K.3    Keith, J.C.4    Schaub, R.G.5
  • 164
    • 38749140235 scopus 로고    scopus 로고
    • Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis
    • Bedard P.W., Clerin V., Sushkova N., Tchernychev B., Antrilli T., Resmini C., et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther 2008, 324:497-506.
    • (2008) J Pharmacol Exp Ther , vol.324 , pp. 497-506
    • Bedard, P.W.1    Clerin, V.2    Sushkova, N.3    Tchernychev, B.4    Antrilli, T.5    Resmini, C.6
  • 165
    • 38949147126 scopus 로고    scopus 로고
    • Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation
    • Meier T.R., Myers D.D., Wrobleski S.K., Zajkowski P.J., Hawley A.E., Bedard P.W., et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost 2008, 99:343-351.
    • (2008) Thromb Haemost , vol.99 , pp. 343-351
    • Meier, T.R.1    Myers, D.D.2    Wrobleski, S.K.3    Zajkowski, P.J.4    Hawley, A.E.5    Bedard, P.W.6
  • 168
    • 77954962134 scopus 로고    scopus 로고
    • New steroidal glycosides isolated as CDL inhibitors of activated platelets
    • Chen H., Ou W., Wang G., Wang N., Zhang L., Yao X. New steroidal glycosides isolated as CDL inhibitors of activated platelets. Molecules 2010, 15:4589-4598.
    • (2010) Molecules , vol.15 , pp. 4589-4598
    • Chen, H.1    Ou, W.2    Wang, G.3    Wang, N.4    Zhang, L.5    Yao, X.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.